MedTrace Logo

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

NCT00700258 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1520

Last updated 2024-09-23

Study results available
· View outcomes & findings →

Summary

The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use

Conditions

  • Carcinoma, Renal Cell, Advanced
  • Lymphoma, Mantle-Cell
  • Gastrointestinal Stroma Tumors

Interventions

DRUG

Temsirolimus

Non-interventional study. Treatment decision already made before inclusion into the registry.

DRUG

Temsirolimus

Non-interventional study. Treatment decision already made before inclusion into the registry.

DRUG

Sunitinib

Non-interventional study. Treatment decision already made before inclusion into the registry.

DRUG

Sunitinib

Non-interventional study. Treatment decision already made before inclusion into the registry.

DRUG

Axitinib

Non-interventional study. Treatment decision already made before inclusion into the registry.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-13
Primary Completion
2021-12-28
Completion
2021-12-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00700258 on ClinicalTrials.gov